Bentley Pharmaceuticals Acquires Rights in Spain to Product for Treating Parkinson's Disease.TAMPA, Fla.--(BUSINESS WIRE)--June 1, 1999-- Bentley Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange : BNT BNT Bentley Pharmaceuticals, Inc. (stock symbol) BNT Boston Naming Test (psychology) BNT Bermuda National Trust BNT Bulgarian National TV BNT Broadband Network Termination BNT Binary File Transfer ), an international manufacturer, marketer, distributor and developer of pharmaceutical products, announced today that it has acquired from Helm Iberia, S.A. the rights in Spain to all data covering formulation of medicines containing Selegiline, a product for treating Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. . Helm Iberia, S.A. is a division of the German pharmaceutical company, Helm AG. Under terms of the agreement with Helm Iberia, Bentley obtained non-exclusive rights to register and commercialize Selegiline in Spain and obtained an option until June 22, 1999 to register and commercialize Selegiline products to Chile and Morocco. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. the IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. , the Spanish market for anti-Parkinson's drugs is approximately $36.5 million annually, and has grown 25 percent over the past 12 months. Bentley is preparing regulatory dossiers that it will submit to Spanish regulatory authorities within the next few months. James R. Murphy, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bentley Pharmaceuticals, said, "This product is an important addition to our rapidly expanding line of pharmaceuticals for the Spanish market, and represents a vote of confidence in Bentley by another international pharmaceutical company." Bentley also announced that it has initiated the relocation of its headquarters from Tampa, Florida “Tampa” redirects here. For other uses, see Tampa (disambiguation). Tampa is a United States city in Hillsborough County, on the west coast of Florida. It serves as the county seat for Hillsborough County.GR6. to 65 Lafayette Road, North Hampton, NH 03862, where the company has established a new pharmaceutical formulations laboratory. The relocation is expected to be complete effective June 30, 1999. The company's new telephone number will be (603) 964-8006, and its fax number will be (603) 964-6889. Bentley Pharmaceuticals, Inc. is an emerging international pharmaceutical company focused on improving drugs through new drug delivery technologies which it intends to commercialize in the U.S. and other major markets in collaboration with other pharmaceutical companies and on the manufacturing, marketing and distribution of products in Europe, Asia, Northern Africa, and Central and South America for the treatment of cardiovascular, gastrointestinal, neurological and infectious diseases. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, the ability to find effective market distribution channels, development of new products, regulatory approval processes, the impact of competitive products or pricing, unpredictability of patent protection, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission. Copies of the company's press releases and other information may be obtained through Bentley's web site at www.bentleypharm.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion